Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?
Naunyn Schmiedebergs Arch Pharmacol
; 394(5): 997-1001, 2021 05.
Article
in English
| MEDLINE | ID: covidwho-1014115
ABSTRACT
Chloroquine and hydroxychloroquine belong to the aminoquinoline drugs. Studies revealed that chloroquine and hydroxychloroquine shows antagonism activity against COVID-19 under laboratory conditions. ARDS and ALI are conditions that occur in patients with COVID-19 as the main pathological complications of cytokine storm. Inflammasomes play a key role in the pathogenesis of many diseases associated with destructive inflammation. NLRP3 inflammasome has been shown to play a key role in the pathogenesis of viral diseases. The possible role of NLRP3 inflammasome inhibitors in the treatment of COVID-19 has been considered. We surveyed the potential inhibitory effect of chloroquine and hydroxychloroquine on inflammasome. Studies indicate that one of the possible anti-inflammatory mechanisms of chloroquine and hydroxychloroquine is inhibition of the activity of NLRP3 inflammasome.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Chloroquine
/
Inflammasomes
/
NLR Family, Pyrin Domain-Containing 3 Protein
/
COVID-19 Drug Treatment
/
Hydroxychloroquine
/
Anti-Inflammatory Agents
Type of study:
Observational study
Limits:
Humans
Language:
English
Journal:
Naunyn Schmiedebergs Arch Pharmacol
Year:
2021
Document Type:
Article
Affiliation country:
S00210-020-02034-6
Similar
MEDLINE
...
LILACS
LIS